With nearly two decades of experience in oncology and men’s health, Paul is an epidemiologist and medical device specialist focused on the early detection of prostate cancer, genomic and germline testing, patient risk stratification, and targeted focal therapy. His career has centered on advancing prostate biopsy methodologies, 3D precision diagnostics, and medical device innovation, working closely with leading urologists and training physicians and residents on modern biopsy techniques. Paul played a key role in the design, development, and FDA 510(k) clearance of multiple biopsy technologies, including the Triopsy® Adjustable Core System, overseeing clinical research, usability, and human-factors studies. Paul has authored more than 40 peer-reviewed publications and abstracts and is a frequent speaker at national and international medical conferences. He holds advanced training in epidemiology and medical device development.